Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive
Myeloproliferative Neoplasm
Explore 70 assets in Myeloproliferative Neoplasm →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03970096CT.gov Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | — | Recruiting | — | — | — |
NCT02661035CT.gov Allo HSCT Using RIC for Hematological Diseases | — | Completed | — | — | — |
NCT01660607CT.gov Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloproliferative Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive (this asset) | Fred Hutchinson Cancer Center | P2 | BB · 64 |
| Melphalan | Center for International Blood and Marrow Transplant Research | P2/3 | BBB |
| Fludarabine | Sawa Ito, MD | P4 | BB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2/3 | BB |
| Nivestim | City of Hope Medical Center | P3 | BB |
| Romidepsin | Sawa Ito, MD | P4 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2/3 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
| Cyclosporin A | City of Hope Medical Center | P3 | BB |
+42 more in the Myeloproliferative Neoplasm cohort
Other indications for Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P2/3 | BBB · 74 |
| Graft Versus Host Disease | — | P2/3 | BB · 67 |
| Myelodysplastic Syndrome | — | P2/3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive in Myeloproliferative Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/peripheral-blood-stem-cells-allogeneic-cd34-positive-myeloproliferative-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →